HIV vaccine candidate VIR-1388 passes early safety check in 93 volunteers

NCT ID NCT05854381

Completed ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new HIV vaccine called VIR-1388 in 93 healthy adults who did not have HIV. The goal was to see if the vaccine is safe and whether it triggers an immune response. Participants received either the vaccine or a placebo, and researchers monitored side effects and immune cell activity. The trial is now complete, and results will help decide if further testing is warranted.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV I INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV I INFECTION

Contacts and locations

Locations

Alabama CRS

Birmingham, Alabama, 35222, United States
Beth Israel Deconess Medical Center VCRS

Boston, Massachusetts, 32077, United States
Chatsworth Clinical Research Site

Overport, KwaZulu-Natal, 4092, South Africa
Isipingo Clinical Research Site

Isipingo, KwaZulu-Natal, 4110, South Africa
Penn Prevention CRS

Philadelphia, Pennsylvania, 19104, United States
Perinatal HIV Research Unit

Soweto, Gauteng, 1862, South Africa
Seattle Vaccine and Prevention CRS

Seattle, Washington, 98104, United States
Setshaba Research Centre CRS

Soshanguve, Gauteng, 0152, South Africa
The Hope Clinic of the Emory Vaccine Center CRS

Decatur, Georgia, 30030, United States
University of Pittsburgh CRS

Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.